CDK9 inhibitors in cancer research-Reference-Cited by-同舟云学术

CDK9 inhibitors in cancer research

Published:2022 Issue:6 Volume:13 Page:688-710
ISSN:2632-8682
Container-title:RSC Medicinal Chemistry
language:en
Short-container-title:RSC Med. Chem.

Author:

Huang Zhi¹²,Wang Tianqi¹,Wang Cheng¹,Fan Yan¹^ORCID

Affiliation:

1. Department of Medicinal Chemistry, School of Medicine, Nankai University, 94 Weijin Road, Tianjin 300071, China

2. Anhui Province Key Laboratory of Medical Physics and Technology, Institute of Health and Medical Technology, Hefei Institutes of Physical Science, Chinese Academy of Sciences, Hefei 230031, China

Abstract

This review outlines the representative CDK9 inhibitors in cancer research and application.

Funder

National Natural Science Foundation of China

Publisher

Royal Society of Chemistry (RSC)

Subject

Organic Chemistry,Drug Discovery,Pharmaceutical Science,Pharmacology,Molecular Medicine,Biochemistry

Link

http://pubs.rsc.org/en/content/articlepdf/2022/MD/D2MD00040G

Reference160 articles.

1. Cdks, cyclins and CKIs: roles beyond cell cycle regulation

2. Targeting Cyclin-Dependent Kinases in Human Cancers: From Small Molecules to Peptide Inhibitors

3. Targeting Cyclin-Dependent Kinases for Treatment of Gynecologic Cancers

4. Structural insights of cyclin dependent kinases: Implications in design of selective inhibitors

5. Cell cycle, CDKs and cancer: a changing paradigm

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. New strategies in soft tissue sarcoma treatment;Journal of Hematology & Oncology;2024-09-02

2. Transcriptional regulation and therapeutic potential of cyclin-dependent kinase 9 (CDK9) in sarcoma;Biochemical Pharmacology;2024-08

3. CDK9 Inhibition by Dinaciclib Is a Therapeutic Vulnerability in Epithelioid Hemangioendothelioma;Clinical Cancer Research;2024-07-25

4. OTUD1 promotes hypertensive kidney fibrosis and injury by deubiquitinating CDK9 in renal epithelial cells;Acta Pharmacologica Sinica;2023-12-18

5. Discovery of KB-0742, a Potent, Selective, Orally Bioavailable Small Molecule Inhibitor of CDK9 for MYC-Dependent Cancers;Journal of Medicinal Chemistry;2023-11-15